Precision Layer 7 Cortical Interface

Learning Objectives

• Understand how the Layer 7 Cortical Interface works and why the non-penetrating approach matters
• Identify the key milestones: FDA clearance, Medtronic partnership, and Johns Hopkins clinical results
• Evaluate how Precision's approach compares to penetrating (Neuralink) and endovascular (Synchron) BCIs

What Is the Precision Layer 7 Cortical Interface?

The Layer 7 Cortical Interface is a brain-computer interface (BCI) developed by Precision Neuroscience that places a thin-film electrode array directly on the surface of the brain — without penetrating brain tissue. The device is one-fifth the thickness of a human hair and conforms to the contours of the cortical surface like a sheet of tissue paper, recording neural signals from 1,024 electrodes simultaneously.

The name "Layer 7" refers to the outermost layer of the cerebral cortex — the surface layer where the device sits. Unlike penetrating BCIs (such as Neuralink's N1), the Layer 7 does not push electrodes into brain tissue, avoiding the inflammatory response and tissue damage that can degrade signal quality over time with penetrating arrays.

Precision Neuroscience was founded by Benjamin Rapoport, a co-founder of Neuralink who left to pursue what he believed was a safer and more scalable approach to brain-computer interfaces. The company received FDA 510(k) clearance in April 2025 and announced a Medtronic partnership in January 2026 to co-develop integrated surgical navigation for implantation. In a 2026 Johns Hopkins study, four patients demonstrated real-time cursor control and speech classification using the Layer 7 device.

Access

The Layer 7 Cortical Interface is currently available only through clinical trials at partner institutions.

Precision Neuroscience works with neurosurgical centers conducting clinical studies. Visit precisionneuro.io for information about research collaborations and trial participation.

Core Capabilities

Non-Penetrating Cortical Recording

The Layer 7's defining technical characteristic is that it records from the brain surface without penetrating tissue. The thin-film array — thinner than one-fifth of a human hair — is placed on the cortical surface through a craniotomy (a small surgical opening in the skull). Because no electrodes pierce brain tissue, the device avoids the chronic inflammatory response that degrades signal quality in penetrating arrays over months and years.

This approach positions the Layer 7 between endovascular BCIs (like Synchron's Stentrode, which reads through blood vessel walls) and penetrating BCIs (like Neuralink's N1, which inserts electrodes into brain tissue). It offers higher signal resolution than endovascular approaches while avoiding the tissue damage of penetrating ones.

High-Density Recording

With 1,024 electrodes, the Layer 7 provides significantly higher spatial resolution than most competing BCIs. More electrodes means more data points from the cortical surface, enabling finer-grained decoding of neural activity. The Johns Hopkins study demonstrated this density translating to practical capability: patients achieved real-time cursor control (moving a pointer on screen using thought) and speech classification (the system identifying intended words from neural patterns).

Medtronic Surgical Navigation Partnership

The January 2026 partnership with Medtronic — the world's largest medical device company — is strategically significant. Medtronic is co-developing integrated surgical navigation tools specifically for Layer 7 implantation. This means the placement procedure will be guided by Medtronic's established neuronavigation systems, improving precision, reducing surgical time, and leveraging Medtronic's existing relationships with neurosurgical centers worldwide.

Strengths

• Non-penetrating: Does not pierce brain tissue — avoids chronic inflammatory response that degrades penetrating electrodes over time
• High electrode count: 1,024 electrodes provide dense cortical coverage and fine-grained signal resolution
• FDA 510(k) clearance: Regulatory milestone achieved April 2025 — a foundation for further clinical development
• Medtronic partnership: Co-development with the world's largest medical device company provides surgical navigation expertise, manufacturing scale, and clinical distribution networks
• Clinical results: Johns Hopkins study demonstrated real-time cursor control and speech classification in 4 patients
• Founded by Neuralink co-founder: Deep technical expertise in BCI design with a deliberate choice of a less invasive approach

Limitations & Considerations

• Requires craniotomy: Unlike Synchron's endovascular approach, the Layer 7 requires opening the skull — a more invasive procedure than catheter-based implantation
• Clinical trials only: Not commercially available — regulatory timeline for broad clinical use is uncertain
• Surface signals only: Cortical surface recording captures less detailed signals than electrodes placed within brain tissue — a tradeoff for safety
• Small patient population: The 2026 Johns Hopkins study included 4 patients — long-term data across larger populations is needed
• Current device is wired: The implanted version used in trials requires a wired connection — the fully wireless chronically implantable version is still in development
• Limited to research institutions: Available only at partner neurosurgical centers participating in clinical studies

Best Use Cases

When to consider alternatives:

• Lowest surgical risk → Synchron Stentrode (endovascular, no craniotomy, 20-minute procedure)
• Highest signal resolution → Neuralink N1 (penetrating electrodes in brain tissue, highest signal fidelity)
• Non-invasive option → EEG-based BCIs (no surgery at all, but significantly lower accuracy and speed)
• Commercial availability → No high-performance BCI is commercially available yet — all are investigational

Key Takeaways

• The Precision Layer 7 Cortical Interface places 1,024 electrodes on the brain surface without penetrating tissue — balancing signal quality and safety
• FDA 510(k) clearance (April 2025) and a Medtronic partnership (January 2026) provide regulatory and commercial foundations that most BCI companies lack
• Clinical results at Johns Hopkins demonstrated real-time cursor control and speech classification in 4 patients using the device
• The Layer 7 occupies a middle ground between endovascular BCIs (less invasive, lower resolution) and penetrating BCIs (more invasive, higher resolution) — offering a non-penetrating approach with high electrode density